GNI files pirfenidone for pulmonary fibrosis in China
This article was originally published in Scrip
Executive Summary
GNI's wholly owned Chinese subsidiary, Shanghai Genomics, has filed for the domestic approval of its lead development project, pirfenidone (F647), for the indication of idiopathic pulmonary fibrosis (IPF).